| Literature DB >> 35004989 |
Zhan-Ru Wang1, Jia-Wu Zhou2, Xiao-Ping Liu2, Guo-Juan Cai3, Qi-Hong Zhang3, Jun-Fang Mao4.
Abstract
BACKGROUND: Epidemiological studies have found that the prevalence of chronic heart failure in China is 0.9%, the number of people affected is more than 4 million, and the 5-year survival rate is even lower than that of malignant tumors. AIM: To determine the impact of WeChat platform-based health management on severe chronic heart failure patients' health and self-management efficacy.Entities:
Keywords: Adverse cardiovascular events; Cardiac function; Health management; Self-care capacity; Severe chronic heart failure; WeChat platform
Year: 2021 PMID: 35004989 PMCID: PMC8686122 DOI: 10.12998/wjcc.v9.i34.10576
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Comparison of baseline data between the two groups, n (%)
|
|
|
|
|
|
| Gender | 0.543 | 0.461 | ||
| Male | 36 (75.00) | 32 (53.33) | ||
| Female | 24 (35.00) | 28 (46.67) | ||
| Age (yr) | 58.69 ± 10.13 | 59.41 ± 11.05 | 0.372 | 0.711 |
| Course (yr) | 6.36 ± 1.24 | 6.24 ± 1.57 | 0.465 | 0.643 |
| History of smoking | 1.234 | 0.267 | ||
| Yes | 22 (36.67) | 28 (46.67) | ||
| No | 38 (63.33) | 32 (53.33) | ||
| NYHA classification | 0.534 | 0.465 | ||
| Ⅲ | 31 (51.67) | 27 (45.00) | ||
| Ⅳ | 29 (48.33) | 33 (55.00) | ||
| Heart-based diseases | 2.394 | 0.495 | ||
| Dilated cardiomyopathy | 5 (8.33) | 9 (15.00) | ||
| Rheumatic heart disease | 10 (16.67) | 12 (20.00) | ||
| Coronary heart disease | 18 (30.00) | 19 (31.67) | ||
| High blood pressure | 27 (45.00) | 20 (33.33) | ||
| Combined diseases | ||||
| Hyperlipidemia | 15 (25.00) | 21 (35.00) | 1.429 | 0.232 |
| Hypertension | 30 (50.00) | 33 (55.00) | 0.301 | 0.583 |
| Diabetes | 19 (31.67) | 15 (25.00) | 0.657 | 0.418 |
| Education | 1.295 | 0.523 | ||
| Junior high school and below | 12 (20.00) | 9 (15.00) | ||
| Secondary and tertiary | 24 (40.00) | 21 (35.00) | ||
| Undergraduate and above | 24 (40.00) | 30 (50.00) |
Comparison of heart function between the two groups (mean ± SD)
|
|
|
|
| ||
|
|
|
|
| ||
| Control | 60 | 34.23 ± 4.26 | 48.23 ± 4.63 | 91.02 ± 5.87 | 103.22 ± 6.32 |
| Observation | 60 | 33.97 ± 4.51 | 60.44 ± 4.58 | 89.63 ± 6.87 | 112.02 ± 5.78 |
|
| 0.325 | 14.522 | 1.191 | 7.959 | |
|
| 0.746 | 0.000 | 0.236 | 0.000 | |
P < 0.05 vs before intervention. LVEF: Left ventricular ejection fraction; SV: stroke output.
Comparison of 6-min walking distance, high-sensitivity cardiac troponin, N-terminal pro B-type natriuretic peptide between the two groups
|
|
|
|
|
| |||
|
|
|
|
|
|
| ||
| Control | 60 | 352.69 ± 57.89 | 468.22 ± 67.41 | 0.70 ± 0.22 | 0.48 ± 0.15 | 3.85 ± 0.24 | 2.78 ± 0.16 |
| Observation | 60 | 346.85 ± 62.08 | 519.36 ± 57.23 | 0.72 ± 0.21 | 0.37 ± 0.12 | 3.87 ± 0.25 | 1.95 ± 0.14 |
|
| 0.533 | 4.480 | 0.509 | 4.436 | 0.447 | 30.240 | |
|
| 0.595 | 0.000 | 0.611 | 0.000 | 0.656 | 0.000 | |
P < 0.05 vs before intervention. 6MWD: 6-min walking distance; hs-cTnT: High-sensitivity cardiac troponin; NT-proBNP: N-terminal pro b-type natriuretic peptide.
Comparison of Self-Care Ability Scale scores between the two groups (mean ± SD, subdivision)
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| ||
| Control | 60 | 19.16 ± 2.94 | 21.13 ± 2.32 | 19.85 ± 3.56 | 22.34 ± 3.69 | 27.84 ± 3.65 | 31.17 ± 4.69 | 18.69 ± 3.85 | 23.12 ± 3.55 |
| Observation | 60 | 18.97 ± 3.02 | 22.78 ± 3.17 | 19.74 ± 3.62 | 24.87 ± 4.05 | 28.01 ± 3.94 | 35.23 ± 4.47 | 18.75 ± 4.05 | 25.78 ± 4.18 |
|
| 0.349 | 3.254 | 0.168 | 3.577 | 0.245 | 4.854 | 0.083 | 3.757 | |
|
| 0.728 | 0.001 | 0.867 | 0.001 | 0.807 | 0.000 | 0.934 | 0.000 | |
P < 0.05 vs before intervention.
Comparison of Minnesota heart failure quality of life scores between the two groups (mean ± SD, subdivision)
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| ||
| Control | 60 | 19.24 ± 2.46 | 15.63 ± 2.01 | 13.56 ± 2.12 | 11.36 ± 1.75 | 13.23 ± 1.85 | 11.47 ± 1.38 | 8.78 ± 1.34 | 7.24 ± 1.03 |
| Observation | 60 | 19.15 ± 2.73 | 11.67 ± 1.45 | 13.61 ± 2.08 | 10.02 ± 1.51 | 13.30 ± 1.76 | 9.58 ± 1.05 | 8.83 ± 1.29 | 5.48 ± 0.87 |
|
| 0.190 | 12.376 | 0.130 | 4.491 | 0.212 | 8.443 | 0.208 | 10.111 | |
|
| 0.850 | 0.000 | 0.896 | 0.000 | 0.832 | 0.000 | 0.835 | 0.000 | |
P < 0.05 vs before intervention.
Comparison of compliance scores between the two groups (mean ± SD, subdivision)
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| ||
| Control | 60 | 5.78 ± 1.32 | 7.23 ± 1.45 | 6.23 ± 0.85 | 8.24 ± 0.63 | 5.41 ± 0.96 | 7.58 ± 0.78 | 5.32 ± 1.14 | 7.41 ± 0.82 |
| Observation | 60 | 5.82 ± 1.07 | 8.69 ± 1.12 | 6.21 ± 0.76 | 9.23 ± 0.57 | 5.32 ± 1.05 | 8.75 ± 0.63 | 5.37 ± 1.03 | 8.68 ± 0.67 |
|
| 0.182 | 6.172 | 0.136 | 9.026 | 0.490 | 9.039 | 0.252 | 9.290 | |
|
| 0.856 | 0.000 | 0.892 | 0.000 | 0.625 | 0.000 | 0.801 | 0.000 | |
P < 0.05 vs before intervention.
Comparison of adverse cardiovascular events between the two groups
|
|
|
|
|
|
| |
|
|
| |||||
| Control | 60 | 5 (8.33) | 8 (13.33) | 6 (10.00) | 17 (28.33) | 16.25 ± 4.23 |
| Observation | 60 | 2 (3.33) | 2 (3.33) | 3 (5.00) | 7 (11.67) | 14.36 ± 3.12 |
|
| 1.365 | 3.927 | 1.081 | 5.208 | 2.785 | |
|
| 0.243 | 0.048 | 0.298 | 0.022 | 0.006 | |